Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Although immune mechanisms can suppress tumour growth, tumours establish potent, overlapping mechanisms that mediate immune evasion. Emerging evidence suggests a link between angiogenesis and the tolerance of tumours to immune mechanisms. Hypoxia, a condition that is known to drive angiogenesis in tumours, results in the release of damage-associated pattern molecules, which can trigger the rejection of tumours by the immune system. Thus, the counter-activation of tolerance mechanisms at the site of tumour hypoxia would be a crucial condition for maintaining the immunological escape of tumours. However, a direct link between tumour hypoxia and tolerance through the recruitment of regulatory cells has not been established. We proposed that tumour hypoxia induces the expression of chemotactic factors that promote tolerance. Here we show that tumour hypoxia promotes the recruitment of regulatory T (T(reg)) cells through induction of expression of the chemokine CC-chemokine ligand 28 (CCL28), which, in turn, promotes tumour tolerance and angiogenesis. Thus, peripheral immune tolerance and angiogenesis programs are closely connected and cooperate to sustain tumour growth.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Hypoxia, through HIF-1α, drives the conversion of MDSCs into antigen-nonspecific suppressors of T cell function and promotes the differentiation of MDSCs into immune-suppressive TAMs, further potentiating the immune-suppressive network [80].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [80]
In the citing paper
“For example, both HIF-1α and HIF-2α induce the production of CCL28, which promotes the recruitment of MDSCs into hepatocellular tumors, whereas HIF-1α induces production of CCL26 that enhances recruitment of Tregs into ovarian tumors (Table 1) [69, 70].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [69]
In the citing paper
“For example, both HIF-1α and HIF-2α induce the production of CCL28, which promotes the recruitment of MDSCs into hepatocellular tumors, whereas HIF-1α induces production of CCL26 that enhances recruitment of Tregs into ovarian tumors (Table 1) [69, 70].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [69]
In the citing paper
“In addition to increasing drug resistance, a high SS could influence tumor cells' gene expression, comprise immune cells ability to kill cancerous cells or even turn macrophages to tumorfriendly cells, thereby enhancing the metastatic potential of cancer cells [180-184].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [181]
In the citing paper
“tumours secrete soluble factors, such as C-C-motif chemokine ligand 2 (CCL2), CCL28, C-X-C-motif chemokine ligand 8 (CXCL8), CXCL12, ANG2, VEGF, PlGF, and adenosine, all of which promote the recruitment of immunosuppressive cells7,17–20 (FIG. 2)”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [17]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Self-citationSummaries of Affymetrix GeneChip probe level data
Irizarry, R. A. (2003) · Nucleic Acids Research · doi:10.1093/nar/gng015 · Cited by 4,887
Camp, R. L., Dolled-Filhart, M., & Rimm, D. L. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0713 · Cited by 3,744
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Self-citationImmunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057
Oncogenic pathway signatures in human cancers as a guide to targeted therapies
Bild, A. H., Yao, G., Chang, J. T., Wang, Q., Potti, A., Chasse, D., Joshi, M.-B., Harpole, D., Lancaster, J. M., Berchuck, A., et al. (2006) · Nature · doi:10.1038/nature04296 · Cited by 2,032
Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
Tothill, R. W., Tinker, A. V., George, J., Brown, R., Fox, S. B., Lade, S., Johnson, D. S., Trivett, M. K., Etemadmoghadam, D., Locandro, B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0196 · Cited by 1,467
Adaptive immunity maintains occult cancer in an equilibrium state
Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., Smyth, M. J., & Schreiber, R. D. (2007) · Nature · doi:10.1038/nature06309 · Cited by 1,436
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314
Cited by
Items 501–600 of 1,002
Immune Microenvironment of Thyroid Cancer
Yin, H., Tang, Y., Guo, Y., & Wen, S. (2020) · Journal of Cancer · doi:10.7150/jca.44506 · Cited by 64
“The secretion of immunosuppressive factors such as transforming growth factor (TGF)-β, vascular endothelial growth factor (VEGF), and indoleamine2,3-dioxygenase (IDO) have modulatory effects on Tregs [16].”
BackgroundInfluentialImmune‐related signature predicts the prognosis and immunotherapy benefit in bladder cancer
Wang, Y., Chen, L., Yu, M., Fang, Y., Qian, K., Wang, G., Ju, L., Xiao, Y., & Wang, X. (2020) · Cancer Medicine · doi:10.1002/cam4.3400 · Cited by 61
Immune Modulator and Low-Temperature PTT-Induced Synergistic Immunotherapy for Cancer Treatment
Duan, Y., Yang, H. N., Gao, J., Wei, D., Zhang, Y., Wang, J., Zhang, X., Zhang, J., Ge, K., Wu, X., et al. (2021) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c01397 · Cited by 54
Bose, S., Saha, P., Chatterjee, B., & Srivastava, A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.03.028 · Cited by 59
Li, J., Qiao, H., Wu, F., Sun, S., Feng, C., Li, C., Yan, W., Lv, W., Wu, H., Liu, M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.998140 · Cited by 62
“Hypoxia attenuates anti-tumor immunity by increasing the pro-tumorigenic M2 phenotype, intratumoral accumulation of immunosuppressive regulatory T cells, and stimulation of adenosine receptors (12, 24, 25).”
BackgroundOxygen levels at the time of activation determine T cell persistence and immunotherapeutic efficacy
Cunha, P. P., Minogue, E., Krause, L. C. M., Hess, R. M., Bargiela, D., Wadsworth, B. J., Barbieri, L., Brombach, C., Foskolou, I. P., Bogeski, I., et al. (2023) · eLife · doi:10.7554/elife.84280 · Cited by 61
“For example, tumour hypoxia recruits immunosuppressive regulatory T cells, which can inhibit CD8+ T cell function (Facciabene et al., 2011).”
BackgroundWang, W., Zhao, Z., Ma, S., Yu, G., Liu, B., Zhang, L., Zhang, W., Kulkarni, A. B., Sun, Z., & Zhao, Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119723 · Cited by 57
Self-citationMasuelli, L., Granato, M., Benvenuto, M., Mattera, R., Bernardini, R., Mattei, M., d’Amati, G., D’Orazi, G., Faggioni, A., Bei, R., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1356151 · Cited by 54
“Interestingly also CCL28 release appears to be dependent on HIF 1a expression.(42) These evidences suggest that HIF 1a, highly expressed in CURCCQ treated tumor cells, could play also indirect pro-tumorigenic effects through the recruitment of T regulatory cells, in addition to its direct pro-survival effect on the tu…”
BackgroundInfluentialTuccitto, A., Shahaj, E., Vergani, E., Ferro, S., Huber, V., Rodolfo, M., Castelli, C., Rivoltini, L., & Vallacchi, V. (2018) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-018-2477-z · Cited by 56
“Hypoxia not only supports Tregs, but, by inducing the production of the CCL-28 and CCL-2 chemokines in cancer cells, it also facilitates the recruitment of CCR10-positive Tregs and CCR2-positive MDSCs [57, 58].”
BackgroundMetabolic reprogramming of T regulatory cells in the hypoxic tumor microenvironment
Nair, V. S., Saleh, R., Toor, S. M., Cyprian, F. S., & Elkord, E. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02842-y · Cited by 60
Underlying mechanisms and drug intervention strategies for the tumour microenvironment
Li, H., Zhou, L., Zhou, J., Li, Q., & Ji, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01893-y · Cited by 56
“The hypoxic state of the TME increases the recruitment of Tregs by inducing the expression of chemokine CC-chemokine ligand 28 (CCL28), which promotes the immunosuppression of the TME [62].”
BackgroundEpigenetic regulation of human FOXP3+ Tregs: from homeostasis maintenance to pathogen defense
Yue, Y., Ren, Y., Lu, C., Li, P., & Zhang, G. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1444533 · Cited by 56
Verona, F., Bella, S. D., Schirano, R., Manfredi, C., Angeloro, F., Bozzari, G., Todaro, M., Giannini, G., Stassi, G., & Veschi, V. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1529847 · Cited by 56
“Indeed, in several cancers, Tregs promote stemness-related pathways (104), facilitate EMT (105) and angiogenesis (101).”
The immunological effect of hyaluronan in tumor angiogenesis
Spinelli, F. M., Vitale, D. L., Demarchi, G., Cristina, C., & Alaniz, L. D. (2015) · Clinical & Translational Immunology · doi:10.1038/cti.2015.35 · Cited by 55
Giatromanolaki, A. N., Harris, A. L., Banham, A. H., Contrafouris, C., & Koukourakis, M. I. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0756-3 · Cited by 54
Hypoxic preconditioning protects against ischemic kidney injury through the IDO1/kynurenine pathway
Torosyan, R. O., Huang, S., Bommi, P. V., Tiwari, R., An, S. Y., Schonfeld, M. P., Rajendran, G., Kavanaugh, M. A., Gibbs, B. K., Truax, A. D., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109547 · Cited by 54
“On the other hand, among the upregulated genes, Cxcl12 promotes kidney repair by facilitating glycolysis (Yakulov et al., 2018), while Ccl28 has been implicated in dampening inflammation in hypoxic tumors by promoting the recruitment of regulatory T (Treg) cells (Facciabene et al., 2011).”
Zhao, Q. S., He, X., Qin, X., Liu, Y., Jiang, H., Wang, J., Wu, S., Zhou, R., Yu, C., Liu, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.938439 · Cited by 54
“Also, inadequate oxygen supply caused by the impaired tumor blood vessels results in tumor hypoxia and hypoxia-mediated immune exhaustion, attenuating the killing ability of effector immune cells (26, 27).”
BackgroundTarabichi, M., Antoniou, A., Saiselet, M., Pita, J. M. G., Andry, G., Dumont, J. E., Detours, V., & Maenhaut, C. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9431-y · Cited by 52
“Hypoxia induces escape from innate immunity through HIF and Adam10 [157] and promotes tolerance via Treg cells [158].”
BackgroundInducing and Administering Tregs to Treat Human Disease
Perdigoto, A. L., Chatenoud, L., Bluestone, J. A., & Herold, K. C. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00654 · Cited by 49
“Furthermore, CCL28 positive tumors can recruit Tregs where they have a proangiogenic role (87).”
BackgroundCCL27/CCL28–CCR10 Chemokine Signaling Mediates Migration of Lymphatic Endothelial Cells
Karnezis, T., Farnsworth, R. H., Harris, N. C., Williams, S. P., Caesar, C., Byrne, D. J., Herle, P., Macheda, M. L., Shayan, R., Zhang, Y., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-1858 · Cited by 63
“In a second experiment, 200 mL of Matrigel was injected containing 4 mg/mL VEGFA, 4 mg/mL VEGFD, 2 mg/mL CCL27, 4 mg/mL VEGFD plus 2 mg/mL CCL27, or PBS þ 0.1% BSA.”
BackgroundInfluentialAngiogenesis in Lymph Nodes Is a Critical Regulator of Immune Response and Lymphoma Growth
Menzel, L., Höpken, U. E., & Rehm, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.591741 · Cited by 55
Pivotal factors associated with the immunosuppressive tumor microenvironment and melanoma metastasis
Zhang, C., Dang, D., Cong, L., Sun, H., & Cong, X. (2021) · Cancer Medicine · doi:10.1002/cam4.3963 · Cited by 53
Sun, S., Ma, J., Xie, P., Wu, Z., & Tian, X. (2020) · The Journal of Gene Medicine · doi:10.1002/jgm.3230 · Cited by 54
Zheng, W., Qian, C., Tang, Y., Yang, C., Zhou, Y., Shen, P., Chen, W., Yu, S., Wei, Z., Wang, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1035323 · Cited by 53
“Tregs exert significant effects on inhibiting the function of IFN-g-expressing CD4 Th1 cells and producing the secretion of VEGF through hypoxiamediated CCL-28, which both strikingly result in a proangiogenic tumor microenvironment (72) (Figure 3).”
BackgroundUltrasound stiffness and perfusion markers correlate with tumor volume responses to immunotherapy
Voutouri, C., Mpekris, F., Panagi, M., Krolak, C., Michael, C., Martin, J. D., Averkiou, M. A., & Stylianopoulos, T. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.06.007 · Cited by 51
Bridging angiogenesis and immune evasion in the hypoxic tumor microenvironment
Schito, L. (2018) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00209.2018 · Cited by 52
Hong, M. M. Y., & Vareki, S. M. (2022) · Cancers · doi:10.3390/cancers14061580 · Cited by 55
Zhang, T., & Sentman, C. L. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201314 · Cited by 53
“In addition, MDSCs and Tregs have been shown to promote tumor angiogenesis (37, 38).”
BackgroundCarvalho, M. I., Pires, I. C. R., Prada, J., Gregório, H., Lobo, L., & QUEIROGA, F. L. (2016) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2016.06.006 · Cited by 63
Halvorsen, E. C., Franks, S. E., Wadsworth, B. J., Harbourne, B. T., Cederberg, R. A., Steer, C. A., Martinez-Gonzalez, I., Calder, J., Lockwood, W. W., & Bennewith, K. L. (2019) · OncoImmunology · doi:10.1080/2162402x.2018.1527497 · Cited by 49
“In addition to immune suppression, Tregs may also facilitate tumour progression through the production of RANKL to suppress the EMT inhibitor maspin,(7) or by secretion of pro-angiogenic VEGFA.(37) Emerging literature indicates Tregs also promote tissue repair in the lungs by producing the growth factor AREG in respon…”
BackgroundDCE-MRI of Tumor Hypoxia and Hypoxia-Associated Aggressiveness
Gaustad, J., Hauge, A., Wegner, C. S., Simonsen, T. G., Lund, K. V., Hansem, L. M. K., & Rofstad, E. K. (2020) · Cancers · doi:10.3390/cancers12071979 · Cited by 53
Recent advances in the role of Th17/Treg cells in tumor immunity and tumor therapy
Qianmei, Y., Su, Z., Wang, G., Li, H., & Lian, G. (2021) · Immunologic Research · doi:10.1007/s12026-021-09211-6 · Cited by 56
Chasing Immune Checkpoint Inhibitors in Ovarian Cancer: Novel Combinations and Biomarker Discovery
Colombo, I., Karakasis, K., Sneha, S., & Oza, A. M. (2023) · Cancers · doi:10.3390/cancers15123220 · Cited by 53
“The presence of malfunctional blood vessels induces immunosuppression through different mechanisms such as an increased expression of PD-L1, a reduced infiltration of cytotoxic T-cells but an increased activation of Tregs and an infiltration of MDSC [71,72].”
BackgroundIn situ immunomodulation of tumors with biosynthetic bacteria promote anti-tumor immunity
Lin, Z., Meng, F., Ma, Y., Zhang, C., Zhang, Z., Yang, Z., Li, Y., Hou, L., Xu, Y., Liang, X., et al. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.09.007 · Cited by 66
The heterogeneous immune microenvironment in breast cancer is affected by hypoxia-related genes
Duechler, M., Pęczek, Ł., Żuk, K., Zaleśna, I., Jeziorski, A., & Czyż, M. (2013) · Immunobiology · doi:10.1016/j.imbio.2013.09.003 · Cited by 49
“Also Treg cells are recruited into the hypoxic tumor through the chemokine ligand 28 (CCL28) (Facciabene et al., 2011), and FoxP3 is up-regulated by hypoxia through Hif-1 (Ben-Shoshan et al., 2008).”
BackgroundChang, W. H., Forde, D., & Lai, A. G. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1775-9 · Cited by 47
The role of T helper 17 and regulatory T cells in tumor microenvironment
Najafi, S., & Mirshafiey, A. (2019) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2019.1566925 · Cited by 50
Hypoxia: Turning vessels into vassals of cancer immunotolerance
Schito, L., & Rey, S. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.05.015 · Cited by 49
Retooling Cancer Nanotherapeutics’ Entry into Tumors to Alleviate Tumoral Hypoxia
Sun, X. J., Ni, N., Ma, Y., Wang, Y., & Leong, D. T. (2020) · Small · doi:10.1002/smll.202003000 · Cited by 47
Rewiring of purine metabolism in response to acidosis stress in glioma stem cells
Xu, X., Wang, L., Zang, Q., Li, S., Li, L., Wang, Z., He, J., Qiang, B., Han, W., Zhang, R., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03543-9 · Cited by 48
Self-citationImmunogenomic cancer evolution: A framework to understand cancer immunosuppression
Kumagai, S., Momoi, Y., & Nishikawa, H. (2025) · Science Immunology · doi:10.1126/sciimmunol.abo5570 · Cited by 53
Hu, B., Yang, X., & Sang, X. (2020) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s272109 · Cited by 57
Anti-Angiogenic Therapy in the Treatment of Non-Small Cell Lung Cancer
Tian, W., Cao, C., Shu, L., & Wu, F. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s276150 · Cited by 51
Gong, P.-J., Shao, Y.-C., Huang, S., Zeng, Y., Yuan, X., Xu, J., Yin, W., Wei, L., & Zhang, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.579868 · Cited by 49
“CCL28 is an inducer of Tregs and has an immunosuppressive function on CD8+ T cells (38).”
BackgroundTumor resident regulatory T cells
Glasner, A., & Plitas, G. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101476 · Cited by 51
More than a scaffold: Stromal modulation of tumor immunity
Johansson, A., Hamzah, J., & Ganß, R. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.06.001 · Cited by 49
“Melanoma cells engineered to express CCL21 induce ectopic LN structures which attract MDSCs, Tregs and naïve T cells and as such enhance local T cell infiltration but fail to prime an adaptive anti-tumor immune response [105].”
BackgroundInfluentialRegulation of Chemokine Expression in the Tumor Microenvironment
Gorbachev, A. V., & Fairchild, R. L. (2014) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2014010062 · Cited by 50
Overcoming physical stromal barriers to cancer immunotherapy
Chung, S. W., Xie, Y., & Suk, J. S. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-01036-y · Cited by 54
An immunocompetent mouse model of human glioblastoma
Semenkow, S., Li, S., Kahlert, U. D., Raabe, E. H., Xu, J., Arnold, A., Janowski, M., Oh, B. C., Brandacher, G., Bulte, J. W. M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17851 · Cited by 49
“Low oxygen tension has been reported to recruit regulatory T-cells that not only induce tolerance of the host immune system to cancer cells, but also stimulate tumor vessel progression [28].”
BackgroundAnti-angiogenesis: Opening a new window for immunotherapy
Guo, F., & Cui, J. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118163 · Cited by 49
Role of chemokines in hepatocellular carcinoma (Review)
Xue, D., Zheng, Y., Wen, J., Han, J., Tuo, H., Liu, Y., & Peng, Y. (2020) · Oncology Reports · doi:10.3892/or.2020.7906 · Cited by 49
“Other CC members, such as CCL28, promote the infiltration of Tregs into the tumor environment, induce angiogenesis and facilitate tumor cell escape from immune surveillance (65).”
BackgroundPan, P., Yue, Q., Li, J., Gao, M., Yang, X., Ren, Y., Cheng, X., Cui, P., & Deng, Y. (2021) · Advanced Science · doi:10.1002/advs.202004586 · Cited by 51
Design strategies and applications of smart optical probes in the second near-infrared window
Chang, B., Chen, J., Bao, J., Dong, K., Chen, S., & Cheng, Z. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114637 · Cited by 50
Research advance of natural products in tumor immunotherapy
Huo, J., Fu, W.-J., Liu, Z.-H., Lü, N., Jia, X.-Q., & Liu, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.972345 · Cited by 49
“Similar to M2 macrophages, Treg cells can inhibit the release of cytokines from Th1 cells and promote angiogenesis in the tumor microenvironment (57).”
BackgroundCell Death Conversion under Hypoxic Condition in Tumor Development and Therapy
Qiu, Y., Li, P., & Ji, C. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161025536 · Cited by 51
“Hypoxia also could promote the recruitment of regulatory T (Treg) cells and then facilitate peripheral immune tolerance and angiogenesis in turn, which sustain tumor growth [69].”
BackgroundHatziioannou, A., Alissafi, T., & Verginis, P. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.5vmr1116-493r · Cited by 47
Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC
Ross‐Macdonald, P., Walsh, A. M., Chasalow, S. D., Ammar, R., Papillon‐Cavanagh, S., Szabó, P. M., Choueiri, T. K., Sznol, M., & Wind‐Rotolo, M. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001506 · Cited by 52
Wen, X., Xiong, X., Yang, G., Xiao, W., Hou, J., Pan, T., Hu, Y., & Zhou, S. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.12.001 · Cited by 45
Napoletano, C., Ruscito, I., Bellati, F., Zizzari, I. G., Rahimi, H., Gasparri, M. L., Antonilli, M., Panici, P. B., Rughetti, A., & Nuti, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8030380 · Cited by 43
Jiang, Z. L., He, L., Yu, X., Yang, Z., Wu, W., Wang, X., Mao, R., Cui, D., Chen, X. S., & Li, W. (2021) · ACS Nano · doi:10.1021/acsnano.1c01063 · Cited by 44
Raykov, Z., Grekova, S. P., Bour, G., Lehn, J., Giese, N. A., Nicolau, C. S., & Aprahamian, M. (2013) · International Journal of Cancer · doi:10.1002/ijc.28597 · Cited by 46
“Ineffective vasculature can block the access of immune cells to the tumor, or provoke immune tolerance of the infiltrating ones.(28) With respect to the immune system, we discovered that in the long term, ITPP therapy improved the influx of T cells (rat model) and of peritoneal macrophages in both rat and nude mouse o…”
BackgroundMouse Models of Tumor Immunotherapy
Ngiow, S. F., Loi, S., Thomas, D. M., & Smyth, M. J. (2016) · Advances in immunology · doi:10.1016/bs.ai.2015.12.004 · Cited by 44
The role and significance of VEGFR2+ regulatory T cells in tumor immunity
Zhu, P., Hu, C., Hui, K., & Jiang, X. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s142085 · Cited by 47
“With an increase in the number of surface molecules such as neuropilin-1 (NRP-1), VEGF, especially VEGFR2 found in VEGFR2+ Tregs,(14) itself can synthesize and secrete angiogenic factors that directly regulate tumor angiogenesis.(15) The influence of angiogenesis on Tregs should also be noted.”
T cells in the post-ischemic brain: Troopers or paramedics?
Cramer, J. V., Benakis, C., & Liesz, A. (2018) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2018.11.006 · Cited by 48
An emerging role of regulatory T-cells in cardiovascular repair and regeneration
Fung, T. H. W., Yang, Y., & Lui, K. O. (2020) · Theranostics · doi:10.7150/thno.47118 · Cited by 45
“In addition, hypoxic conditions cause Treg to secrete significantly higher amount of VEGFA, and the culture medium of hypoxic Treg is able to induce the expansion of CD31+ endothelial cells in vitro, leading to significantly greater capillary endothelial network, suggesting an important role for Treg in tumour angioge…”
BackgroundA Window of Opportunity: Targeting Cancer Endothelium to Enhance Immunotherapy
Duru, G., van Egmond, M., & Heemskerk, N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.584723 · Cited by 48
“Hypoxic zones in tumors also attract MDSCs (21, 51, 52), tumor associated macrophages (TAMs) (22, 53) and regulatory T cells (Treg cells) (23, 54).”
BackgroundInfluentialLi, H.-X., Wang, S., Lian, Z., Deng, S., & Yu, K. (2022) · Cells · doi:10.3390/cells12010064 · Cited by 51
“Besides that, the recruitment of Tregs to tumors under hypoxic conditions is also through the combination of CCL28 and CCR10 [124].”
BackgroundMetabolites and Immune Response in Tumor Microenvironments
Cortellino, S., & Longo, V. D. (2023) · Cancers · doi:10.3390/cancers15153898 · Cited by 45
“Furthermore, Bregs support pancreas and gastric cancer by secreting IL35, which is a potent anti-inflammatory cytokine produced mainly by Tregs cells [92,93].”
BackgroundInfluentialAdvances in promoting chimeric antigen receptor T cell trafficking and infiltration of solid tumors
Hong, M., Talluri, S., & Chen, Y. Y. (2023) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2023.103020 · Cited by 51
Cross-Talk Between Cancer and Its Cellular Environment—A Role in Cancer Progression
Turlej, E., Domaradzka, A., Radzka, J., Drulis‐Fajdasz, D., Kulbacka, J., & Gizak, A. (2025) · Cells · doi:10.3390/cells14060403 · Cited by 50
Ibberson, M. R., Bron, S., Guex, N., Hull, E. F.-V., Ifticene‐Treboux, A., Henry, L., Lehr, H., Delaloye, J.-F., Coukos, G., Xénarios, I., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3181 · Cited by 47
Self-citationJoseph, R. W., Parasramka, M. A., Eckel‐Passow, J. E., Serie, D., Wu, K. J., Jiang, L., Kalari, K. R., Thompson, R. H., Ho, T. H., Castle, E. P., et al. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0042 · Cited by 43
The Role of Chemoattractant Receptors in Shaping the Tumor Microenvironment
Zhou, J., Xiang, Y., Yoshimura, T., Chen, K., Gong, W., Huang, J., Zhou, Y., Yao, X., Bian, X., & Wang, J. (2014) · BioMed Research International · doi:10.1155/2014/751392 · Cited by 46
“Moreover, Tregs expressing CCR10 are capable of accelerating angiogenesis through secreting VEGF in response to CCL28 produced by hypoxic tumor cells for EC infiltration and participation in angiogenesis [35].”
BackgroundInfluentialPhenotypic and Functional Properties of Tumor-Infiltrating Regulatory T Cells
Lee, G. R. (2017) · Mediators of Inflammation · doi:10.1155/2017/5458178 · Cited by 52
“The CCL5/CCR5 axis also plays a role in Treg cell recruitment [27], and hypoxia-induced CCL28 has been found to attract CCR10 Treg cells into ovarian cancers [28].”
BackgroundJiang, Z., Xiong, H., Yang, S., Lü, Y., Deng, Y., Yao, J., & Yao, J. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202000075 · Cited by 43
Zhang, J., Yang, M., Fan, X., Zhu, M., Yin, Y., Li, H., Chen, J., Qin, S., Zhang, H., Zhang, K., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01324-w · Cited by 43
Kheshtchin, N., & Hadjati, J. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30643 · Cited by 44
“As such, hypoxia‐induced expression of CCL28 promotes the recruitment of Treg cells in the TME (Facciabene et al., 2011).”
BackgroundÖncül, S., & Cho, M. S. (2023) · Cancers · doi:10.3390/cancers15041282 · Cited by 41
“Tregs are recruited and activated by the hypoxic conditions in ovarian cancer TME [276] and are abundant in ascites.”
BackgroundMetabolic advantages of regulatory T cells dictated by cancer cells
Kondo, M., Kumagai, S., & Nishikawa, H. (2023) · International Immunology · doi:10.1093/intimm/dxad035 · Cited by 44
Role of tumor microenvironment in ovarian cancer metastasis and clinical advancements
Wang, Y., Zhu, N., Liu, J., Chen, F., Song, Y., Ma, Y., Yang, Z., & Wang, D. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06508-0 · Cited by 56
Immunometabolism of regulatory T cells in cancer
Saravia, J., & Chi, H. (2025) · Oncogene · doi:10.1038/s41388-025-03458-1 · Cited by 52
Yin, J., Cao, H., Wang, H., Sun, K., Li, Y., & Zhang, Z. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.06.004 · Cited by 42
Defining and Predicting Early Recurrence after Resection for Gallbladder Cancer
Sahara, K., Tsilimigras, D. I., Kikuchi, Y., Ethun, C. G., Maithel, S. K., Abbott, D. E., Poultsides, G. A., Hatzaras, I. S., Fields, R. C., Weiss, M. J., et al. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-09108-y · Cited by 41
Zhang, L., Zhang, M., Jin-xiu, X., Li, S., Chen, Y., Wang, W., Yang, J., Li, S., & Gu, M. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-6719 · Cited by 43
“Tregs are attracted to the tumor bed by vascular endothelial growth factor (VEGF) or chemokines (such as CCL17, CCL22, CCL28, and CXCL12) secreted by tumor cells or immune cells (44,46).”
BackgroundSelf-citationLiu, Q., Palmgren, V. A. C., Danen, E. H. J., & Dévédec, S. E. L. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07802-6 · Cited by 48
Targeting Angiogenesis via Resolution of Inflammation
Kelly, A. G., & Panigrahy, D. (2022) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041172 · Cited by 48
Tang, Y., Yu, X., He, L., Tang, M., Yue, W., Chen, R., Zhao, J., Pan, Q., & Li, W. (2025) · Nature Communications · doi:10.1038/s41467-025-56110-7 · Cited by 49
Control of the Adaptive Immune Response by Tumor Vasculature
Mauge, L., Terme, M., Tartour, É., & Helley, D. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00061 · Cited by 49
Cerium- and Iron-Oxide-Based Nanozymes in Tissue Engineering and Regenerative Medicine
Jansman, M. M. T., & Hosta‐Rigau, L. (2019) · Catalysts · doi:10.3390/catal9080691 · Cited by 41
Benoit, A., Vogin, G., Duhem, C., Berchem, G., & Janji, B. (2023) · Cells · doi:10.3390/cells12131787 · Cited by 39
“function of MDSCs by inducing the expression of VISTA on myeloid cells [136].”
BackgroundPerspectives on Hypoxia Signaling in Tumor Stroma
Zhang, Y., Coleman, M., & Brekken, R. A. (2021) · Cancers · doi:10.3390/cancers13123070 · Cited by 39
Chemokine Heterocomplexes and Cancer: A Novel Chapter to Be Written in Tumor Immunity
D’Agostino, G., Cecchinato, V., & Uguccioni, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02185 · Cited by 42
Metabolic factors contribute to T‐cell inhibition in the ovarian cancer ascites
Gong, Y., Yang, J., Wang, Y., Xue, L., & Wang, J. (2020) · International Journal of Cancer · doi:10.1002/ijc.32990 · Cited by 46
Intratumor Regulatory Noncytotoxic NK Cells in Patients with Hepatocellular Carcinoma
Zecca, A., Barili, V., Rizzo, D., Olivani, A., Biasini, E., Laccabue, D., Valle, R. D., Ferrari, C. I., Cariani, E., & Missale, G. (2021) · Cells · doi:10.3390/cells10030614 · Cited by 44
“Local production of soluble mediators, among which IL-10 and TGF-β promoted by hypoxia, may be responsible for modulation of these receptors [44,46,47].”
The Interplay Between Inflammation and Stromal Components in Pancreatic Cancer
Li, Y., Wang, J., Wang, H., Zhang, S., Wei, Y., & Liu, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.850093 · Cited by 49
“Under hypoxia, tumor cells recruit Tregs by upregulating the expression of chemokine ligand 28 (CCL28), enhancing tumor immune tolerance and promoting angiogenesis (106).”
BackgroundThe Interplay between T Cells and Cancer: The Basis of Immunotherapy
Chen, C., Liu, X., Chang, C., Wang, H. Y., & Wang, R. (2023) · Genes · doi:10.3390/genes14051008 · Cited by 46
“Under hypoxic conditions, tumor cells and associated cells secrete cytokines and factors that attract Tregs to the TME [278].”
BackgroundDeng, J., Liu, X., Rong, L., Chen, N., Li, X., Yang, W. C., Lu, Y., Yan, X., Qin, C., Zhang, L., et al. (2014) · The Journal of Pathology · doi:10.1002/path.4340 · Cited by 46
Self-citationLi, H., Lei, W., Wu, J., Li, S., Zhou, G., Liu, D., Yang, X., Wang, S., Li, Z., & Zhang, J. (2018) · Journal of Materials Chemistry B · doi:10.1039/c8tb00637g · Cited by 39
CCL7 Signaling in the Tumor Microenvironment
Lee, Y. S., & Cho, Y. B. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-36667-4_4 · Cited by 42
Refolo, M. G., Lotesoriere, C., Messa, C., Caruso, M. G., & D’Alessandro, R. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.4mr0120-221r · Cited by 51
Metadata
- Authors
- Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L.-P., Gimotty, P. A., Gilks, C. B., Lal, P., Zhang, L., & Coukos, G.
- Affiliations
- University of Pennsylvania (US)
- University of British Columbia (CA)
- Corresponding author
- Coukos, George
- ORCID
- Venue
- Nature
- Published
- 2011-07
- Volume
- 475
- Issue
- 7355
- Pages
- 226-230
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2142644858
- Cited by
- 1,376
- References
- 38
- Citations by year
- 2026: 54 · 2025: 90 · 2024: 112 · 2023: 113 · 2022: 151 · 2021: 152 · 2020: 119 · 2019: 105 · 2018: 77 · 2017: 85 · 2016: 74 · 2015: 55 · 2014: 55 · 2013: 69 · 2012: 50
- FWCI
- 26.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (R01CA116779, P01 CA 83638)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- tumor hypoxia, regulatory T cells, CCL28, chemokine recruitment, tumor angiogenesis, VEGF-A, tumor immune evasion, tumor growth, chemokines
- MeSH terms
- Animals, Female, Humans, Immune Tolerance, Mice, Inbred C57BL, Neovascularization, Pathologic, Ovarian Neoplasms, Cell Hypoxia, Gene Expression Regulation, Neoplastic, Culture Media, Conditioned, Disease Progression, Chemokines, CC, Vascular Endothelial Growth Factor A, Cell Line, Tumor, T-Lymphocytes, Regulatory, Mice, Receptors, CCR10
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.